林箐 副研究员（博士生导师）
单位：四川大学华西药学院药剂学系
通讯地址：成都市人民南路三段17号四川大学华西药学院605-3
E-mail:qinglin@scu.edu.cn
教育&工作经历
2009.09–2013.06 四川大学 华西药学院 药学 理学学士
2013.09–2017.06 四川大学 华西药学院 药剂学 理学博士 （3+2+3本硕博连读） 导师：张志荣教授
2017.07–2020.09 四川大学 华西药学院 药剂学系 专职博士后|助理研究员（2017.07）、副研究员（专职科研，2019.05）
2019.01–2020.01 剑桥大学 化学工程与生物技术系 访问研究员 合作教授: Nigel K.H. Slater FREng
2020.09–至今 四川大学华西药学院药剂学系副研究员|硕士生导师（2021.07）、博士生导师（2026.07）
研究方向
靶向药物与长效释药系统研究
承担课题
1.国家重点研发计划（子课题），2024YFA1210101-1，2024.12-2029.11，主持
2.国家自然科学基金，面上项目，82273877，2023.01-2026.12，主持
3.四川省自然科学基金，青年项目，23NSFSC3777，2023.01-2024.12，主持
4.成都市科技项目，2022-YF05-01398-SN，2023.06-2024.05，主持
5.四川大学博士后创新培育项目，2023.03~2024.03，主持
6.国家自然科学基金，青年项目，81803447，2019.01-2021.12，主持
7.中国博士后科学基金，2018M633388，2019.01-2022.12，主持
8.四川大学博士后交叉学科创新启动基金项目，2019. 01-2020.09，主持
9.四川大学专职博士后研发基金，2018SCU12025，2018. 01-2019.12，主持
研究论文
[1]JFu, Y Wang, A Zhang, T Li, Y Yuan, K Chen, S He, L Li, S Huang, L Guo, X Sun, T Gong, L Zhang,Q Lin*, Z Zhang. Reticuloendothelial system blockade-assisted redirection of celastrol-loaded nanomedicine to glomeruli for treatment of mesangioproliferative glomerulonephritis.NanoResearch, 2026,9, 94908676.
[2]G Wei, M Chen, Y Yang, S Qian, Z Li, X Sun, Z Zhang, T Gong, B Zong*,Q Lin*.Solidification intervention strategies for efficient encapsulation of water-soluble drugs via oil-in-water emulsion techniques.Journal of Controlled Release, 2026, 396: 115046.
[3]Y Quan, Y Yuan, K Chen, T Li, J Li, M Zhang, R Shi, He, L Li, X Sun, T Gong, L Zhang, Z Zhang,Q Lin*. A dual pH/ROS-sensitive nanoplatform blocking NETs formation and co-delivering paclitaxel for potent therapeutic efficacy against triple-negative breast cancer and lung metastasis.Nanoscale, 2026, 18: 3312-3330.
[4]S Ma, J Yang, A Li,Q Lin*, T Gong*.Sustainedintra-articulardelivery oftripletherapeuticsusing aphase-transitionphospholipid-basedgel foreffectivetreatment ofgoutyarthritis.Pharmaceutical Research, 2026,10.1007/s11095-026-04134-z.
[5]J Yang, Y Jia, SMa, L Huang, L Zhong, Y Lai, K Qin, A Li,Q Lin*, T Gong*.Fattyacidglyceride-basedlipidmicroparticles as along-actinginjectabledeliverysystem forbrexpiprazole inschizophreniatreatment.Journal of Materials Chemistry B, 2026.
[6]R Shi, J Fu, M Li, A Zhang, S Huang, X Yang, Y Liang, Y Quan, S He, S Huang, L Li, X Sun, T Gong, L Zhang,Q Lin*, Z Zhang. Monocyte membrane-coated drug nanocrystals for enhanced targeted therapy of rheumatoid arthritis.Journal of Controlled Release, 2025, 384: 113919.
[7]H Gao, Y Wang, J Fu, Y Yuan, T Li, A Zhang, W He, S He, S Huang, L Li, M Qu, L Guo, X Sun, T Gong, L Zhang,Q Lin*, Z Zhang. Monocyte membrane-fused liposomes for enhanced targeted treatment of mesangioproliferative glomerulonephritis.ACS Applied Materials & Interfaces, 2025, 17: 67641-67654.
[8]J Fu, S Huang, A Zhang, R Shi, Y Wei, S He, S Huang, L Li, X Sun, T Gong, L Zhang,Q Lin*, Z Zhang. Therapeutic strategies based on macrophages and their derivatives: Targeted drug delivery platforms and disease treatment.Journal of Pharmaceutical Analysis, 2025, 15:101413.
[9]Q Lin, L Zhang, Z Zhang. Oral Delivery of Nanoparticles: Challenges and Opportunities.Oral Bioavailability and Drug Delivery: From Basics to Advanced Concepts and Applications, 2024, 591-598, Wiley Press.
[10]L Zhu, X Yu, T Cao, H Deng, X Tang,Q Lin*, Q Zhou*. Immune cell membrane-based biomimetic nanomedicine for treating cancer metastasis.Acta Pharmaceutica Sinica B,2023, 13:2464-2482.
[11]L Zhu, H Gao, T Wang, G Xiao, C Hu*,Q Lin*, Q Zhou*. Tumor immune microenvironment-modulated nanostrategy for the treatment of lung cancer metastasis.Chinese Medical Journal, 2023, 136:2787-2801.
[12]X Qi, T Zhu, W Hu, W Jiang, J Yang,Q Lin*, Y Wang*. Multifunctional polyacrylamide/hydrated salt/MXene phase change hydrogels with high thermal energy storage, photothermal conversion capability and strain sensitivity for personal healthcare.Composites Science and Technology, 2023,234: 109947.
[13]Q Zhang, Y Han, H Xiang, M Li, L Yang, Q Liu, Y Zhang, Z Zhang,Q Lin*, L Zhang*. Biopharmaceutical, preclinical pharmacokinetic and pharmaco-dynamic investigations of an orally administered novel 3-nbutylphthalide prodrug for ischemic stroke treatment.European Journal of Pharmaceutical Sciences, 2023, 180: 106308.
[14]Y Fu, L Wang, W Liu, L Yang, L Li, L Wang, X Sun, Z Zhang,QLin*, L Zhang*. OX40L blockade cellular nanovesicles for autoimmune diseases therapy.Journal of Controlled Release, 2021, 337: 557-570.
[15]B Zhou, M Li, X Xu, L Yang, M Ye, Y Chen, J Peng, L Xiao, L Wang, S Huang, L Zhang,Q Lin*, Z Zhang. Integrin α2β1targeting DGEA-modified liposomal doxorubicin enhances anti-tumor efficacy against breast cancer.Molecular Pharmaceutics, 2021, 18: 2634-2646.
[16]Q Lin, M Qu, H K. Patra, S He, L Wang, X Hu, L Xiao, Y Fu, T Gong, Q He, L Zhang*, X Sun, Z Zhang. Mechanistic and therapeutic study of novel anti-tumor function of natural compound imperialine for treating non-small cell lung cancer.Journal of Ethnopharmacology, 2020, 247: 112283.
[17]QLin, YLi, M Qu, X Liu, Z Zhang, L Zhang*. Preliminary Investigation on Difference of Protein Compositions Between DC2. 4 Cells and Their Derived Exosomes by nanoLC-MS/MS.Journal of Sichuan University Medical Science, 2020, 51: 81-86.
[18]Q Lin, M Qu, B Zhou, H K. Patra, Z Sun, Q Luo, W Yang, Y Wu, Y Zhang, L Li, L Deng, L Wang, T Gong, Q He, L Zhang*, X Sun, Z Zhang. Exosome-like nanoplatform modified with targeting ligand improves anti-cancer and anti-inflammation effects of imperialine.Journal of Controlled Release, 2019, 311: 104-116.
[19]K Jiang#, X Song#, L Yang, L Li, Z Wan, X Sun, T Gong,Q Lin*, Z Zhang*. Enhanced antitumor and anti-metastasis efficacy against aggressive breast cancer with a fibronectin-targeting liposomal doxorubicin.Journal of Controlled Release, 2018, 271: 21-30.
[20]L Wang, M Qu, S Huang, Y Fu, L Yang, S He, L Li, Z Zhang, Q Lin*, L Zhang*. A novel α-enolase-targeted drug delivery system for high efficacy prostate cancer therapy.Nanoscale, 2018, 10: 13673-13683.
[21]X Hu, M Jia, Y Fu, P Zhang, Z Zhang, Q Lin*. A novel low-toxic derivative of celastrol maintains protective effect against acute renal injury.ACS Omega, 2018, 3 (3): 2652-2660.
[22]Y Fu, W Liu, L Wang, B Zhu, M Qu, L Yang, X Sun, T Gong, Z Zhang,Q Lin*, L Zhang*. Erythrocyte-membrane-camouflaged nanoplatform for intravenous glucose-responsive insulin delivery.Advanced Functional Materials, 2018, 28: 1802250.
